Q3 Earnings Forecast for BOLT Issued By HC Wainwright

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) – Stock analysts at HC Wainwright issued their Q3 2025 earnings estimates for Bolt Biotherapeutics in a report issued on Tuesday, March 25th. HC Wainwright analyst E. White anticipates that the company will post earnings per share of ($0.33) for the quarter. HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Bolt Biotherapeutics’ current full-year earnings is ($1.61) per share.

Bolt Biotherapeutics (NASDAQ:BOLT) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.38) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.38). The business had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.79 million. Bolt Biotherapeutics had a negative return on equity of 69.46% and a negative net margin of 665.56%.

Separately, Stifel Nicolaus cut their price objective on shares of Bolt Biotherapeutics from $1.50 to $1.25 and set a “hold” rating on the stock in a report on Tuesday. Five research analysts have rated the stock with a hold rating, According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $1.13.

Bolt Biotherapeutics Stock Down 0.1 %

Shares of NASDAQ:BOLT opened at $0.44 on Thursday. The business’s 50 day moving average is $0.47 and its 200 day moving average is $0.55. Bolt Biotherapeutics has a 12-month low of $0.38 and a 12-month high of $1.56. The stock has a market cap of $16.82 million, a price-to-earnings ratio of -0.26 and a beta of 0.94. The company has a quick ratio of 3.16, a current ratio of 3.16 and a debt-to-equity ratio of 0.21.

Institutional Trading of Bolt Biotherapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. FMR LLC grew its stake in Bolt Biotherapeutics by 33.2% in the 3rd quarter. FMR LLC now owns 115,386 shares of the company’s stock valued at $75,000 after purchasing an additional 28,773 shares during the period. Millennium Management LLC bought a new position in Bolt Biotherapeutics during the fourth quarter valued at about $25,000. Citadel Advisors LLC purchased a new stake in Bolt Biotherapeutics during the fourth quarter worth about $42,000. Squarepoint Ops LLC purchased a new stake in Bolt Biotherapeutics during the fourth quarter worth about $26,000. Finally, Velan Capital Investment Management LP bought a new stake in Bolt Biotherapeutics in the fourth quarter worth about $27,000. 86.70% of the stock is owned by hedge funds and other institutional investors.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.